Table 2.
Characteristics of 649 protocols, by status at follow-up. Values are numbers (percentages)
| Total (n=649) | Not initiated (n=68) | Ongoing (n=16) | Never completed (n=64) | Completed (n=501) | Published (n=190) | |
|---|---|---|---|---|---|---|
| Study topic | ||||||
| Drug testing | 444 (68) | 42 (62) | 7 (44) | 50 (78) | 345 (69) | 114 (60) |
| Cosmetics, nutrition | 43 (7) | 3 (4) | 0 | 0 | 40 (8) | 6 (3) |
| Medical device testing | 35 (5) | 6 (9) | 1 (6) | 0 | 28 (6) | 12 (6) |
| Surgical and diagnostic procedures | 32 (5) | 6 (9) | 2 (12) | 6 (9) | 18 (4) | 13 (7) |
| Physiology | 48 (7) | 4 (6) | 3 (19) | 2 (3) | 39 (8) | 24 (13) |
| Other | 47 (7) | 7 (10) | 3 (19) | 6 (9) | 31 (6) | 21 (11) |
| Design | ||||||
| Descriptive or observational study | 91 (14) | 12 (18) | 4 (25) | 9 (14) | 66 (13) | 37 (19) |
| Experimental study: | 558 (86) | 56 (82) | 12 (75) | 55 (86) | 435 (87) | 153 (81) |
| Non-randomised | 213 (38) | 22 (39) | 4 (33) | 21 (38) | 166 (38) | 63 (41) |
| Randomised, no blinding | 80 (14) | 6 (11) | 2 (17) | 12 (22) | 60 (14) | 21 (14) |
| Randomised, single blinding | 70 (13) | 8 (14) | 2 (17) | 8 (15) | 52 (12) | 11 (7) |
| Randomised, double blinding | 195 (35) | 20 (36) | 4 (33) | 14 (25) | 157 (36) | 58 (38) |
| Funding | ||||||
| No funding | 54 (8) | 14 (21) | 1 (6) | 8 (13) | 31 (6) | 13 (7) |
| Private funding | 471 (73) | 46 (68) | 7 (44) | 42 (66) | 376 (75) | 113 (59) |
| Public funding | 82 (13) | 7 (10) | 4 (25) | 8 (13) | 63 (13) | 46 (24) |
| Mixed funding | 42 (6) | 1 (1) | 4 (25) | 6 (9) | 31 (6) | 18 (9) |
| Singlev multicentre, scope | ||||||
| National: | 530 (82) | 62 (91) | 12 (75) | 46 (72) | 410 (82) | 140 (74) |
| Single centre | 358 (68) | 43 (69) | 3 (25) | 21 (46) | 291 (71) | 89 (64) |
| Multicentre | 172 (32) | 19 (31) | 9 (75) | 25 (54) | 119 (29) | 51 (36) |
| International multicentre | 119 (18) | 6 (9) | 4 (25) | 18 (28) | 91 (18) | 50 (26) |
| Planned sample size | ||||||
| ≤20 patients | 221 (34) | 24 (35) | 2 (13) | 17 (27) | 178 (36) | 61 (32) |
| 21-50 patients | 177 (27) | 19 (28) | 4 (25) | 23 (36) | 131 (26) | 43 (23) |
| 51-150 patients | 107 (17) | 15 (22) | 1 (6) | 11 (17) | 80 (16) | 34 (18) |
| >150 | 137 (21) | 10 (15) | 9 (56) | 12 (19) | 106 (21) | 48 (25) |
| Not available | 7 (1) | 0 | 0 | 1 (1) | 6 (1) | 4 (2) |
| Planned duration | ||||||
| <2 months | 94 (14) | 5 (7) | 0 | 5 (8) | 84 (17) | 7 (4) |
| 2-5 months | 105 (16) | 7 (10) | 1 (6) | 5 (8) | 92 (18) | 25 (13) |
| 6-18 months | 160 (25) | 19 (28) | 4 (25) | 21 (33) | 116 (23) | 65 (34) |
| >18 months | 113 (17) | 12 (18) | 8 (50) | 16 (25) | 77 (15) | 44 (23) |
| Not available | 177 (27) | 25 (37) | 3 (19) | 17 (27) | 132 (26) | 49 (26) |